Serengeti Asset Management LP Reata Pharmaceuticals Inc Transaction History

Serengeti Asset Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$25.61 - $110.96 $384,150 - $1.66 Million	-15,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$100.0 - $143.02 $1.5 Million - $2.15 Million	15,000 New	15,000 $1.51 Million
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $1.96 Million - $3.78 Million	-25,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $306,090 - $553,860	-3,000 Reduced 10.71%	25,000 $3.09 Million
Q3 2020 Nov 16, 2020	BUY	$93.53 - $163.34 $2.15 Million - $3.76 Million	23,000 Added 460.0%	28,000 $2.73 Million
Q2 2020 Jul 29, 2020	SELL	$126.3 - $176.56 $1.26 Million - $1.77 Million	-10,000 Reduced 66.67%	5,000 $780,000
Q1 2020 May 04, 2020	BUY	$124.16 - $247.74 $1.86 Million - $3.72 Million	15,000 New	15,000 $2.17 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Serengeti Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Serengeti Asset Management LP with notifications on news.